English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare neoplastic primary liver cancer that is also known as mixed HCC-CC since it portrays characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). It constitutes less than 5% of primary liver cancers, hence, the literature lacks guidance on the management of these patients. A handful of case series has been published on clinical features and surgical outcomes. There is next-to-no mention of how to treat these patients. However, surgery has proven the most definitive treatment with varied responses to systemic therapies. We present a case of cHCC-CC in a patient who has undergone multiple treatment modalities, including surgical resection, chemotherapy, immunotherapy, and targeted therapy.

A Patient’s Journey With Rare Biphenotypic Hepatocellular Carcinoma and Cholangiocarcinoma